|Diphenoxylate||Mu opiate receptor agonist|
|Atropine||Muscarinic acetylcholine receptors antagonist|
|Defined daily dose||Not established|
Diphenoxylate/atropine, also known as co-phenotrope, is a combination of the medications diphenoxylate and atropine, used to treat diarrhea. It should not be used in those in whom Clostridioides difficile infection is a concern. It is taken by mouth. Onset is typically within an hour.
Side effects may include abdominal pain, angioedema, glaucoma, heart problems, feeling tired, dry mouth, and trouble seeing. It is unclear if use in pregnancy is safe and use when breastfeeding may result in side effects in the baby. It works by decreasing contractions of the bowel.
The combination was approved for medical use in the United States in 1960. It is available as a generic medication and over the counter. In the United States the wholesale cost per is dose is US$0.31. In 2017, it was the 353rd most commonly prescribed medication in the United States, with more than 700 thousand prescriptions. It is sold under the brand name Lomotil among others. The medication is in Schedule V in the United States.
Absolute contraindications are:
- Allergy to diphenoxylate or atropine
- Diarrhea associated with pseudomembranous enterocolitis, diarrhea caused by antibiotic treatment, or diarrhea caused by enterotoxin-producing bacteria.
- Presence of jaundice
The drug combination is generally safe in short-term use and with recommended dosage. In doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction.
It may cause several side-effects, such as dry mouth, headache, constipation and blurred vision. Since it may also cause drowsiness or dizziness, it should not be used by motorists, operators of hazardous machinery, etc. It is not recommended for children under two years of age.
Interactions with other drugs:
- Antidepressants (e.g. Elavil, Prozac)
- Monoamine oxidase inhibitors (e.g. Nardil, Parnate)
- Opioid analgesics
- Sedatives (e.g. Ambien, Sonata)
It may cause serious health problems when overdosed. Effects may include any of the following: convulsions, respiratory depression (slow or stopped breathing), dilated eye pupils, nystagmus (rapid side-to-side eye movements), erythema (flushed skin), gastrointestinal constipation, nausea, vomiting, paralytic ileus, tachycardia (rapid pulse), drowsiness and hallucinations. Symptoms of toxicity may take up to 12 hours to appear.
Mechanism of action
Diphenoxylate is anti-diarrheal and atropine is anticholinergic. A subtherapeutic amount of atropine sulfate is present to discourage deliberate overdosage. Atropine has no anti-diarrheal properties, but will cause tachycardia when overused. The medication diphenoxylate works by slowing down the movement of the intestines. In some cases it has been shown to ease symptoms of opiate withdrawal.
Society and culture
As of 2018, the combination drug is marketed in the US and some other countries under the following brands: Atridol, Atrolate, Atrotil, Co-Phenotrope, Dhamotil, Dimotil, Intard, Logen, Lomanate, Lomotil, Lonox, and Reasec.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 10 September 2020. CS1 maint: discouraged parameter (link)
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 66. ISBN 9780857113382.
- "Diphenoxylate hydrochloride and atropine sulfate solution". Dailymed. Retrieved 22 March 2019. CS1 maint: discouraged parameter (link)
- "Diphenoxylate and Atropine (Professional Patient Advice)". Drugs.com. Retrieved 22 March 2019. CS1 maint: discouraged parameter (link)
- "Atropine / diphenoxylate Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019. CS1 maint: discouraged parameter (link)
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019. CS1 maint: discouraged parameter (link)
- "Atropine Sulfate; Diphenoxylate Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- "Diphenoxylate and atropine drug information". UpToDate. Retrieved 14 February 2017. CS1 maint: discouraged parameter (link)
- "Diphenoxylate international brands". Drugs.com. Retrieved 11 May 2018. CS1 maint: discouraged parameter (link)
- DEA, Title 21, Section 829